ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Why 10x Genomics (TXG) Stock Is Trading Up Today

TXG Cover Image

What Happened?

Shares of biotech company 10x Genomics (NASDAQ: TXG) jumped 14.3% in the afternoon session after the company reported third-quarter financial results that beat Wall Street's expectations and provided an upbeat revenue forecast for the fourth quarter. 

For the third quarter, revenue came in at $149 million, exceeding the consensus estimate of $142.4 million. The company's loss per share of $0.22 was also narrower than the $0.28 loss analysts had predicted. Looking ahead, 10x Genomics projected fourth-quarter revenue to be in the range of $154 million to $158 million. The midpoint of this guidance surpassed analysts' forecasts, signaling confidence in its performance. Overall, the strong results and positive outlook appeared to drive investor optimism.

The shares closed the day at $15.25, up 17.4% from previous close.

Is now the time to buy 10x Genomics? Access our full analysis report here.

What Is The Market Telling Us

10x Genomics’s shares are extremely volatile and have had 48 moves greater than 5% over the last year. But moves this big are rare even for 10x Genomics and indicate this news significantly impacted the market’s perception of the business.

The previous big move we wrote about was 18 days ago when the stock gained 6% on the news that BofA Securities maintained its "Buy" rating on the stock, even while lowering its price target. The firm adjusted its price target on 10x Genomics to $13.00 from $15.00. While a price target reduction can sometimes signal concern, investors appeared to focus on the reaffirmed positive rating. This suggested continued confidence from the analyst firm in the stock's potential.

10x Genomics is up 7.5% since the beginning of the year, and at $15.26 per share, it is trading close to its 52-week high of $16.47 from December 2024. Investors who bought $1,000 worth of 10x Genomics’s shares 5 years ago would now be looking at an investment worth $113.74.

The biggest winners—Microsoft, Alphabet, Coca-Cola, Monster Beverage—were all riding powerful megatrends before Wall Street caught on. We’ve just identified an under-the-radar profitable growth stock positioned at the center of the AI boom. Get it FREE here before the crowd discovers it. GO HERE NOW.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.41
+0.00 (0.00%)
AAPL  268.47
+0.00 (0.00%)
AMD  233.54
+0.00 (0.00%)
BAC  53.20
+0.00 (0.00%)
GOOG  279.70
+0.00 (0.00%)
META  621.71
+0.00 (0.00%)
MSFT  496.82
+0.00 (0.00%)
NVDA  188.15
+0.00 (0.00%)
ORCL  239.26
+0.00 (0.00%)
TSLA  429.52
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.